Montero-Sánchez P, Islas-Rodríguez JP, García-Guerrero EM, Romero-Rosa S, Cortez-Resendez A

Language: Spanish
References: 13
Page: 201-208
PDF size: 252.68 Kb.

ABSTRACT

Introduction: Diabetes mellitus type 2 is an illness in which the pancreas does not produce suffi cient insulin for the body, or the receptors of the peripheral tissues are down regulated. Linagliptin is a DPP4 inhibitor is used for the treatment of diabetes, and it has shown to have a safety profi le with few side eff ects. Patients with renal insuffi ciency may also benefi t from Linagliptin; it controls hypoglycemic states and reduces the progression of pancreatic beta cell failure. Clinical case: On June 25th 2016, a 74-year-old male reported having symptoms of asthenia, adynamia, anorexia, fever, acholia, choluria, abdominal pain, and jaundice for the past 20 days. Th e patient was on a daily regimen of Sitagliptin and Metformin combination; however, he was prescribed Linagliptin due to non-availability of Sitagliptin. Shortly aft er taking this new medication, his symptomatology began. Aft er several medical exams, doctors came to the conclusion that his symptomatology was due to choledocholithiasis, rather than a side eff ect of the new medication, Linagliptin. Doctors deemed it a coincidence. Comentary: In daily medical practice, the entire medical team should always be aware and vigilant of any new reactions or interactions between drugs, especially with new drugs. Discusion: Although the clinical presentation of the patient was originally thought to be a linagliptin side effect, further evaluation of the patient concluded a diagnosis of choledocholithiasis. However, there is still doubt on linagliptin possible involvement as a triggering factor for this patient’s clinical presentation. Conclusion: It is difficult to conclude an association due to the lack of experience with DPP4 and few documented side effects, therefore it is difficult to fi rmly state a direct association of Linagliptin consumption with this patient’s clinical case.

REFERENCES

1. Defi nition, diagnosis and classifi cation of diabetes mellitus and its complications. Part 1: Diagnosis and classifi cation of diabetes mellitus. Geneva, World Health Organization, 1999 (WHO/ NCD/NCS/99.2).

2. Sergio Zúñiga-Guajardo. René Rodríguez-Gutiérrez. Jorge Yamamoto-Cuevas. Sonia Citlali Juárez-Comboni. Comparación de la efi cacia de los iDPP-4 actualmente disponibles y ventajas antihiperglucemiantes de linagliptina en pacientes con diabetes mellitus 2. Med Int Méx 2015;31:441-453.

3. Linagliptina recomendada para su aprobación en el tratamiento de la diabetes tipo 2 en Europa. Boehringer Ingelheim México y Eli Lilly and Company.23/junio/2016 índice de noticias.

4. Osakidetza. N. Linagliptina cuarto inhibidor de la DPP-4 en el tratamiento de la DM2 y aun con dudas de seguridad a largo plazo. Informe de evaluación completo. 202-2013.

5. Amoros-Paredes A, Martínez-Sesmero JM. Linagliptina. hoja de evaluación de medicamentos de la Castilla-la Mancha. Vol. XIV, No 4. 2013.

6. Linagliptina. Centro Andaluz de documentación e información de medicamentos FEM 2013(1).ISSN:22555773.

7. Patier-Peña JL, González-García A, López-Castellanos G, Sobrino-Grande C. Hepatotoxicidad inducida por linagliptina y sitagliptina: ¿es un efecto de clase?

8. Giordia CB, Sacerdote C, Nada E, Marafetti L, Baldi L. Incretinbased therapies and a cut pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine2015marz, 48 (2) 461-71.PubMed.

9. Linagliptina. Centro Andaluz de documentación e información de medicamentos FEM 2013(1).ISSN:22555773.

10. Zúñiga-Guajardo S, Rodríguez-Gutiérrez R, Yamamoto-Cuevas J, Juárez-Comboni SC. Comparación de la efi cacia de los iDPP- 4 actualmente disponibles y ventajas antihiperglucemiantes de linagliptina en pacientes con diabetes mellitus 2. Med Int Méx 2015;31:441-453.

11. Messori A, Fadda V, Maratea D, et al. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes. Diabetes Th erapy 2014; 5: 341-344.

12. Anexo i fi cha técnica o resumen de las características del producto: linagliptina. Se puede encontrar: http://www.ema.europa.eu/ docs/es_ES/document_library/EPAR_-_Product_Information/ human/002110/WC500115745.pdf.

13. Irineo-Cabrales AB, Zambada-Sentíes C, Garduño-Espinosa J, Mejía-Arreguin H, Vadillo-Ortega F, Osuna-Ramírez I. Construcción de una escala clínica-ultrasonográfi ca para el diagnóstico de coledocolitiasis. Rev. Gastroenterología Mex., Vol. 71, Núm. 3, 2006.